EGFR (C775S/T790M/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.C775S;p.T790M;p.L858R
Components
p.C775Sp.T790Mp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 99.9% | 0.1% | 82.96 |
| 2 | Canertinib | 99.8% | 0.2% | 96.49 |
| 3 | Mobocertinib | 99.7% | 0.3% | 97.22 |
| 4 | Lazertinib | 99.5% | 0.5% | 97.47 |
| 5 | Osimertinib | 99.2% | 0.8% | 97.24 |
| 6 | Afatinib | 98.2% | 1.8% | 98.50 |
| 7 | Dacomitinib | 97.7% | 2.3% | 97.99 |
| 8 | Capmatinib | 95.2% | 4.8% | 99.75 |
| 9 | Fostamatinib | 88.6% | 11.4% | 96.74 |
| 10 | Pralsetinib | 87.2% | 12.8% | 93.43 |
| 11 | Neratinib | 84.9% | 15.1% | 93.18 |
| 12 | Pacritinib | 83.2% | 16.8% | 88.64 |
| 13 | Gilteritinib | 79.5% | 20.5% | 88.97 |
| 14 | Ibrutinib | 74.2% | 25.8% | 94.74 |
| 15 | Ceritinib | 70.8% | 29.2% | 95.44 |
| 16 | Alectinib | 39.0% | 61.0% | 95.49 |
| 17 | Gefitinib | 37.3% | 62.7% | 99.25 |
| 18 | Erlotinib | 28.1% | 71.9% | 99.75 |
| 19 | Deucravacitinib | 28.0% | 72.0% | 98.99 |
| 20 | Bosutinib | 27.6% | 72.4% | 87.22 |
| 21 | Lorlatinib | 27.5% | 72.5% | 97.24 |
| 22 | Vandetanib | 25.2% | 74.8% | 95.74 |
| 23 | Alpelisib | 23.9% | 76.1% | 97.22 |
| 24 | Pirtobrutinib | 18.3% | 81.7% | 99.49 |
| 25 | Dasatinib | 16.8% | 83.2% | 87.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 99.9% | 98.5% | +1.4% |
| Canertinib | 99.8% | 98.4% | +1.3% |
| Mobocertinib | 99.7% | 100.0% | -0.3% |
| Lazertinib | 99.5% | 100.0% | -0.5% |
| Osimertinib | 99.2% | 99.1% | +0.1% |
| Afatinib | 98.2% | 100.0% | -1.8% |
| Dacomitinib | 97.7% | 99.8% | -2.1% |
| Capmatinib | 95.2% | — | — |
| Fostamatinib | 88.6% | 97.8% | -9.2% |
| Pralsetinib | 87.2% | 99.1% | -12.0% |
| Neratinib | 84.9% | 100.0% | -15.1% |
| Pacritinib | 83.2% | — | — |
| Gilteritinib | 79.5% | 91.0% | -11.5% |
| Ibrutinib | 74.2% | 99.3% | -25.2% |
| Ceritinib | 70.8% | — | — |
| Alectinib | 39.0% | — | — |
| Gefitinib | 37.3% | 99.9% | -62.6% |
| Erlotinib | 28.1% | 99.4% | -71.3% |
| Deucravacitinib | 28.0% | — | — |
| Bosutinib | 27.6% | 99.3% | -71.7% |
| Lorlatinib | 27.5% | — | — |
| Vandetanib | 25.2% | 99.3% | -74.2% |
| Alpelisib | 23.9% | — | — |
| Pirtobrutinib | 18.3% | — | — |
| Dasatinib | 16.8% | 97.9% | -81.1% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.7ms